IQV:NYE-IQVIA Holdings Inc.

EQUITY | Medical Diagnostics & Research | New York Stock Exchange

Last Closing

USD 141.3

Change

0.00 (0.00)%

Market Cap

USD 27.87B

Volume

1.09M

Analyst Target

USD 158.65
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-16 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing IQV

EKG First Trust Nasdaq Lux Di.. 8.88 % 0.00 %

+0.30 (+1.81%)

USD 1.51M
BBH VanEck Biotech ETF 4.99 % 0.35 %

+1.88 (+1.81%)

USD 0.45B
IBB iShares Biotechnology ETF 4.48 % 0.47 %

+1.92 (+1.81%)

USD 7.79B
VOT Vanguard Mid-Cap Growth I.. 1.34 % 0.07 %

+2.37 (+1.81%)

USD 24.16B
GNRX 0.00 % 0.55 %

N/A

N/A
IWP iShares Russell Mid-Cap G.. 0.00 % 0.24 %

+0.99 (+1.81%)

USD 15.17B
PBI Pitney Bowes Inc 0.00 % 0.79 %

+0.14 (+1.81%)

USD 0.74B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.03 (+1.81%)

CAD 0.05B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.49 (+1.81%)

CAD 0.05B
MID S&P Midcap 400 0.00 % 0.00 %

+0.36 (+1.81%)

USD 0.07B
VNMC Natixis ETF Trust II - Na.. 0.00 % 0.00 %

+0.41 (+1.81%)

USD 3.88M
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

+0.04 (+1.81%)

USD 1.12B

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.63% 53% F 83% B
Dividend Return N/A N/A N/A N/A F
Total Return 21.63% 47% F 80% B-
Trailing 12 Months  
Capital Gain 36.81% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 36.81% 88% B+ 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 11.28% 35% F 84% B
Dividend Return 11.28% 18% F 80% B-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 16.33% 59% D- 45% F
Risk Adjusted Return 69.05% 29% F 72% C
Market Capitalization 27.87B 83% B 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 111.26 6% 4%
Price/Book Ratio 3.87 47% 19%
Price / Cash Flow Ratio 6.11 47% 17%
Price/Free Cash Flow Ratio 35.86 41% 13%
Management Effectiveness  
Return on Equity 3.51% 18% 35%
Return on Invested Capital 4.50% 29% 29%
Return on Assets 1.14% 24% 37%
Debt to Equity Ratio 146.00% 12% 25%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector